{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:10:57Z","timestamp":1787991057859,"version":"build-2784847793"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI167753"],"award-info":[{"award-number":["R01AI167753"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCSF-Bay Area Center for AIDS Research","award":["P30AI027763"],"award-info":[{"award-number":["P30AI027763"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Long-acting cabotegravir (CAB-LA) is highly effective for HIV prevention, but delayed HIV diagnoses and integrase strand transfer inhibitor (INSTI) resistance were observed in trials. We report the first case in routine clinical care of HIV infection on CAB-LA with INSTI resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The SeroPrEP study enrolls individuals in the United States who acquire HIV on pre-exposure prophylaxis modalities to assess diagnostics, antiretroviral (ARV) drug levels, resistance, and treatment outcomes. Resistance mutations in full-length HIV-1 integrase were identified by single-genome sequencing (SGS). Cabotegravir concentrations in plasma and hair segments were measured by liquid chromatography\u2013tandem mass spectrometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A 23-year-old gender-nonbinary person, male at birth, restarted CAB-LA 6 months after discontinuation due to losing insurance. Prior to restart, HIV-1 RNA was not detected, but 20 days elapsed before CAB-LA injection. After the second CAB-LA injection, HIV antigen\/antibody returned reactive (HIV-1 RNA 451\u2005copies\/mL). SGS of plasma HIV-1 RNA identified INSTI mutation Q148R in 2\/24 sequences 2 days postdiagnosis; commercial genotype failed amplification. Cabotegravir hair concentration was 0.190\u2005ng\/mg 2 weeks prediagnosis; plasma cabotegravir was high (3.37\u2005\u03bcg\/mL; \u223c20\u00d7 PA-IC90) 14 days postdiagnosis. Viral suppression was maintained for 6 months on darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide, then switched to doravirine + emtricitabine\/tenofovir alafenamide due to nausea.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this first case of HIV infection on CAB-LA with INSTI resistance in routine care, cabotegravir resistance was detected only with a sensitive research assay. Accelerated pathways to minimize time between HIV testing and CAB-LA initiation are needed to optimize acute HIV detection and mitigate resistance risk. Sustained product access regardless of insurance is imperative to reduce HIV infections on CAB-LA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae468","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T11:01:51Z","timestamp":1724670111000},"source":"Crossref","is-referenced-by-count":11,"title":["First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7297-175X","authenticated-orcid":false,"given":"Catherine A","family":"Koss","sequence":"first","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-1994","authenticated-orcid":false,"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K","family":"Halvas","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Okochi","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Chu","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David V","family":"Glidden","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Georgetti Gomez","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L","family":"Heaps","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A","family":"Conroy","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tran","sequence":"additional","affiliation":[{"name":"Men's Health Foundation , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Shetler","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Hoeth","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kuncze","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Louie","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Rivera Garza","sequence":"additional","affiliation":[{"name":"University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Wafula Mugoma","sequence":"additional","affiliation":[{"name":"Global Programs for Research and Training , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri J","family":"Penrose","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna H","family":"Chohan","sequence":"additional","affiliation":[{"name":"University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O","family":"Ayieko","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mills","sequence":"additional","affiliation":[{"name":"Men's Health Foundation , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa R","family":"Patel","sequence":"additional","affiliation":[{"name":"Whitman Walker Health , Washington DC ,","place":["USA"]},{"name":"Washington University , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Mellors","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi M","family":"Parikh","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"2024092714532050500_ofae468-B1","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/S2352-3018(23)00261-8","article-title":"Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial","volume":"10","author":"Landovitz","year":"2023","journal-title":"Lancet HIV"},{"key":"2024092714532050500_ofae468-B2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2024092714532050500_ofae468-B3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"2024092714532050500_ofae468-B4","volume-title":"Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention","author":"World Health Organization","year":"2022"},{"key":"2024092714532050500_ofae468-B5","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/infdis\/jiab576","article-title":"Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate\/emtricitabine for HIV prevention: HPTN 084","volume":"225","author":"Eshleman","year":"2022","journal-title":"J Infect Dis"},{"key":"2024092714532050500_ofae468-B6","doi-asserted-by":"crossref","first-page":"e0005323","DOI":"10.1128\/aac.00053-23","article-title":"Extended analysis of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"67","author":"Marzinke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092714532050500_ofae468-B7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s11904-022-00616-y","article-title":"Long-acting injectable cabotegravir for HIV prevention: what do we know and need to know about the risks and consequences of cabotegravir resistance?","volume":"19","author":"Parikh","year":"2022","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024092714532050500_ofae468-B8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1097\/QAD.0000000000003644","article-title":"Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis","volume":"37","author":"Hazra","year":"2023","journal-title":"AIDS"},{"key":"2024092714532050500_ofae468-B9","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/infdis\/jiac415","article-title":"HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention","volume":"226","author":"Eshleman","year":"2022","journal-title":"J Infect Dis"},{"key":"2024092714532050500_ofae468-B10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med"},{"key":"2024092714532050500_ofae468-B11","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000001825","article-title":"Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination","volume":"32","author":"Thaden","year":"2018","journal-title":"AIDS"},{"key":"2024092714532050500_ofae468-B12","first-page":"S2352-3018(18)30288-1","article-title":"Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report","author":"Cohen","year":"2018","journal-title":"Lancet HIV"},{"key":"2024092714532050500_ofae468-B13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/cid\/ciy321","article-title":"Acquisition of multidrug-resistant human immunodeficiency virus type 1 infection in a patient taking preexposure prophylaxis","volume":"67","author":"Colby","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024092714532050500_ofae468-B14","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/cid\/ciaa1011","article-title":"Use of drug-level testing and single-genome sequencing to unravel a case of human immunodeficiency virus seroconversion on pre-exposure prophylaxis","volume":"72","author":"Spinelli","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024092714532050500_ofae468-B15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/tmj.2022.0145","article-title":"Understanding HIV pre-exposure prophylaxis questions of U.S. health care providers: unique perspectives from the PrEPline clinical teleconsultation service","volume":"29","author":"Saberi","year":"2023","journal-title":"Telemed J E Health"},{"key":"2024092714532050500_ofae468-B16","volume-title":"Preexposure Prophylaxis for the Prevention of HIV Infection in the United States\u20142021 Update: A Clinical Practice Guideline","author":"US Public Health Service","year":"2021"},{"key":"2024092714532050500_ofae468-B17","doi-asserted-by":"crossref","first-page":"e01442\u201320","DOI":"10.1128\/JCM.01442-20","article-title":"Automated multireplicate quantification of persistent HIV-1 viremia in individuals on antiretroviral therapy","volume":"58","author":"Jacobs","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2024092714532050500_ofae468-B18","author":"Gandhi"},{"key":"2024092714532050500_ofae468-B19","volume-title":"Consolidated Guidelines on HIV, Viral Hepatitis and STI Prevention, Diagnosis, Treatment and Care for Key Populations","author":"World Health Organization","year":"2022"},{"key":"2024092714532050500_ofae468-B20","author":"Landovitz"},{"key":"2024092714532050500_ofae468-B21","author":"Zhu"},{"key":"2024092714532050500_ofae468-B22","author":"California Prevention Training Center"},{"key":"2024092714532050500_ofae468-B23","doi-asserted-by":"crossref","first-page":"105427","DOI":"10.1016\/j.antiviral.2022.105427","article-title":"Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir","volume":"208","author":"Rhee","year":"2022","journal-title":"Antiviral Res"},{"key":"2024092714532050500_ofae468-B24","author":"Monogram Biosciences"},{"key":"2024092714532050500_ofae468-B25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024092714532050500_ofae468-B26","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"Loosli","year":"2023","journal-title":"Lancet HIV"},{"key":"2024092714532050500_ofae468-B27","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescent","year":"2023"},{"key":"2024092714532050500_ofae468-B28","doi-asserted-by":"crossref","first-page":"e0178737","DOI":"10.1371\/journal.pone.0178737","article-title":"Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention","volume":"12","author":"Patel","year":"2017","journal-title":"PLoS One"},{"key":"2024092714532050500_ofae468-B29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/09540121.2018.1533238","article-title":"Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California","volume":"31","author":"Marcus","year":"2019","journal-title":"AIDS Care"},{"key":"2024092714532050500_ofae468-B30","author":"Patel"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae468\/58919526\/ofae468.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/9\/ofae468\/59361433\/ofae468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/9\/ofae468\/59361433\/ofae468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:53:37Z","timestamp":1727448817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae468\/7741202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae468","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,26]]},"article-number":"ofae468"}}